The stock of Health Catalyst Inc (HCAT) has gone down by -4.98% for the week, with a 21.42% rise in the past month and a 38.68% rise in the past quarter. The volatility ratio for the week is 5.64%, and the volatility levels for the past 30 days are 5.46% for HCAT. The simple moving average for the past 20 days is 6.12% for HCAT’s stock, with a 9.61% simple moving average for the past 200 days.
Is It Worth Investing in Health Catalyst Inc (NASDAQ: HCAT) Right Now?
Moreover, the 36-month beta value for HCAT is 1.32. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 5 as “overweight,” 5 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for HCAT is 57.75M and currently, short sellers hold a 4.06% of that float. On September 27, 2024, HCAT’s average trading volume was 554.76K shares.
HCAT) stock’s latest price update
The stock of Health Catalyst Inc (NASDAQ: HCAT) has increased by 1.94 when compared to last closing price of 8.23. Despite this, the company has experienced a -4.98% fall in its stock price over the last five trading sessions. seekingalpha.com reported 2024-09-24 that I recommend a buy rating for Health Catalyst stock. HCAT’s Ignite platform is gaining traction, offering modular solutions that enhance adoption, cross-sell opportunities, and expand the total addressable market. Despite potential short-term ARPU concerns, Ignite’s higher margins and ongoing migration will drive long-term profitability and significant upside by FY28.
Analysts’ Opinion of HCAT
Evercore ISI, on the other hand, stated in their research note that they expect to see HCAT reach a price target of $11. The rating they have provided for HCAT stocks is “Outperform” according to the report published on January 03rd, 2024.
Barclays gave a rating of “Overweight” to HCAT, setting the target price at $14 in the report published on January 03rd of the current year.
HCAT Trading at 13.94% from the 50-Day Moving Average
After a stumble in the market that brought HCAT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.47% of loss for the given period.
Volatility was left at 5.46%, however, over the last 30 days, the volatility rate increased by 5.64%, as shares surge +23.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.62% upper at present.
During the last 5 trading sessions, HCAT fell by -4.98%, which changed the moving average for the period of 200-days by +8.12% in comparison to the 20-day moving average, which settled at $7.98. In addition, Health Catalyst Inc saw -9.40% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HCAT starting from Llewelyn Linda, who sale 1,324 shares at the price of $8.43 back on Sep 16 ’24. After this action, Llewelyn Linda now owns 115,599 shares of Health Catalyst Inc, valued at $11,161 using the latest closing price.
LINDA LLEWELYN, the Officer of Health Catalyst Inc, proposed sale 1,324 shares at $8.44 during a trade that took place back on Sep 16 ’24, which means that LINDA LLEWELYN is holding shares at $11,175 based on the most recent closing price.
Stock Fundamentals for HCAT
Current profitability levels for the company are sitting at:
- -0.25 for the present operating margin
- 0.35 for the gross margin
The net margin for Health Catalyst Inc stands at -0.29. The total capital return value is set at -0.2. Equity return is now at value -23.15, with -12.22 for asset returns.
Based on Health Catalyst Inc (HCAT), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at -0.02. The debt to equity ratio resting at 0.7. The interest coverage ratio of the stock is -9.32.
Currently, EBITDA for the company is -40.55 million with net debt to EBITDA at -1.45. When we switch over and look at the enterprise to sales, we see a ratio of 1.85. The receivables turnover for the company is 5.34for trailing twelve months and the total asset turnover is 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.18.
Conclusion
To wrap up, the performance of Health Catalyst Inc (HCAT) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
